At the 2013 ACR/ARHP Annual Meeting, study authors presented data on subcutaneous tocilizumab that demonstrated long-term efficacy, including sustained ACR response rate and reduced joint damage progression over 48 weeks.
A high retention rate and improvements in signs/symptoms of rheumatoid arthritis (RA) and in physical function were maintained long-term with golimumab + methotrexate therapy, investigators presented at the 2013 ACR/ARHP Annual Meeting.
Both fostamatinib regimens in the Oskira-1 Study achieved statistical improvements in ACR 20 response rate vs. placebo in patients treated with methotrexate, reported study investigators at the 2013 ACR/ARHP Annual Meeting.
Pregnant women with rheumatoid arthritis (RA) who received an influenza vaccination had a similar incidence of influenza-like illness compared with women without autoimmune disease, a study presented at the 2013 ACR/ARHP Annual Meeting has found.
Patients with acute gouty arthritis who received canakinumab administered via a prefilled syringe experienced significantly greater pain relief and reduced risk of new attacks compared with triamcinolone acetonide, a study reported at the 2013 ACR/ARHP Annual Meeting.
Exposure to glucocorticosteroids was associated with a significant increase in mortality, a finding that has “important implications for health care providers and people with arthritis,” results of a population-based cohort study reported at the 2013 ACR/ARHP Annual Meeting.
Significant increases in bone mineral density (BMD) were observed after 12 months of treatment with denosumab vs. placebo in patients with rheumatoid arthritis (RA) regardless of glucocorticoid use, according to a study presented at the 2013 ACR/ARHP Annual Meeting.
Low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for patients with fibromyalgia, according to results of a prospective, open-label study presented at the 2013 ACR/ARHP Annual Meeting.
A significantly smaller increase in total corticosteroid dose was seen in the belimumab treatment arms than standard therapy alone for patients with systemic lupus erythematosus (SLE), reported study investigators at the 2013 ACR/ARHP Annual Meeting.
Aspirin is a viable option in patients with systemic lupus erythematosus (SLE) at risk for—or who have had—arterial thrombosis, a study presented at the 2013 ACR/ARHP Annual Meeting concluded.
